Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | CPS1 | P31327 | 5/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25634091 | 1.00 | USP30 (0.44) | USP30MYCCPS1SIRT6ALDH1A1 | |
| SCHEMBL31032891 | 0.89 | ALDH1A1 (0.46) | MYCSIRT6ALDH1A1KDM4EMAPT | |
| SCHEMBL20976852 | 0.85 | CPS1 (0.43) | USP30CPS1SIRT6ALDH1A1HPGD | |
| SCHEMBL20954152 | 0.83 | CPS1 (0.44) | USP30CPS1 | |
| SCHEMBL19096982 | 0.83 | CPS1 (0.44) | USP30CPS1 | |
| SCHEMBL20976884 | 0.82 | MAPT (0.51) | USP30SIRT6ALDH1A1KDM4EMAPT | |
| SCHEMBL24696583 | 0.82 | KDM4E (0.44) | USP30MYCSIRT6ALDH1A1KDM4E | |
| SCHEMBL30525392 | 0.82 | ALDH1A1 (0.41) | USP30ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL25634092 | 0.82 | ALDH1A1 (0.41) | USP30ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL16608992 | 0.81 | RAB9A (0.53) | USP30SIRT6ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4438603-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-10-02 | — | — | EP | disclosed |
| CN-118234726-A | Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AR, NR5A1, CYP17A1 | USP30 2399/4885MYC 113/4885CPS1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.